PT-141 (Bremelanotide) vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | Substance P |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |